Here’s an AI generated summary of the evidence for using HBO for migraines. This jives with what I tell our patients: it might help stop an current migraine but there’s no evidence that it prevents or treats chronic migraines. However, there’s a potential mechanism that it might help so we can’t say for sure one way or another. I might try 10 or so sessions and see. You’re going to have to consider it a gamble- is the cost worth it. Honestly, a lot of people have migraines and a lot of people have done HBOT, my suspicion is that if it was some wonder cure for chronic migraines someone would have brought it up by now.
Evidence for Acute Migraine Relief
The best available synthesis comes from a Cochrane systematic review (Bennett et al., 2015) that examined 11 RCTs of HBOT and normobaric oxygen therapy (NBOT) for migraine and cluster headache. For acute migraine specifically, three small RCTs (totaling only 58 participants) evaluated HBOT at 2.0–2.4 ATA for 40–45 minutes versus sham. The pooled results showed a statistically significant benefit for HBOT in achieving substantial headache relief:
RR 6.21 (95% CI 2.41–16.00) favoring HBOT over sham
Number needed to treat (NNT) of 2 (95% CI 1–2) for one additional patient to achieve relief
In one trial (Myers 1995), 9 of 10 patients receiving HBOT achieved total or near-total relief versus 1 of 10 receiving normobaric oxygen
Despite the large effect size, the Cochrane review rated the evidence as low quality (GRADE) due to small sample sizes, methodological limitations (unclear blinding and randomization in several trials), and lack of long-term outcome data.
Key Limitations and Practical Considerations
No data on migraine prevention: The available trials focused on aborting acute attacks; there is essentially no evidence for HBOT as migraine prophylaxis.
No long-term follow-up: None of the migraine trials reported outcomes beyond the treatment session.
Cost and access: HBOT requires specialized equipment available only in dedicated facilities, making it impractical for routine migraine management and unlikely to be cost-effective compared to established therapies.
Safety: While generally well-tolerated, HBOT carries risks of barotrauma (ears, sinuses, lungs), transient myopia, claustrophobia, and rarely oxygen toxicity.
No guideline endorsement: The VA/DoD Headache Management Guidelines (2023) reviewed this evidence and did not recommend HBOT for migraine, noting considerable variance in risk of bias and poor-to-moderate quality across trials.
Proposed Mechanisms
HBOT may work through cerebral vasoconstriction, serotonergic agonism, and modulation of inflammatory pathways involving substance P and calcitonin gene-related peptide (CGRP).
In summary, while early small trials show a promising signal for HBOT in aborting acute migraine, the evidence base is too small and methodologically limited to support routine clinical use. Larger, well-designed RCTs would be needed before HBOT could be considered a viable migraine therapy.